The document outlines the 2007 business goals of Biogen Idec, including goals set by the CEO, CFO and management, and VP of R&D. The CEO's goal of having 100,000 patients on TYSABRI was not met. The CFO and management's goal of over 40% of revenue coming from international business was not met. The VP of R&D's goals of four new products launched or in new indications and six late-stage clinical programs were not met. The regulatory goal of six late-stage programs was achieved.

2. The Brains and the Goals behind Biogen Idec
Business Goals as of 2007:
CEO:
George A. Scangos -- 100,000 patients on TYSABRI(R) (natalizumab);
Not yet met.
CFO & Management: -- More than 40% of the Company's revenue coming from
Paul Clancy its International business;
Not yet met.
VP of R&D: -- Four new products and/or existing products launched in
Douglas new indications;
Williams
Not yet met.
-- Six programs in late-stage clinical development.
Regulatory:
Nadine Cohen Goal achieved.

3. References
• http://www.biogenidec.com/about.aspx?ID=5468
• http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/EnforcementA
ctivitiesbyFDA/WarningLettersandNoticeofViolati
onLetterstoPharmaceuticalCompanies/UCM1660
71.pdf
• http://www.biogenidec.com/PRESS_RELEASE_DE
TAILS.aspx?ID=5981&ReqId=1086798
• http://www.msrc.co.uk/index.cfm/fuseaction/sh
ow/pageid=1905